Table 3: Clinical trials combining the EGF receptor antagonists with other signaling pathway inhibitors.

American Society of Clinical Oncology (ASCO) 2009 Annual Meeting Proceedings

Phase I trial of bevacizumab + everolimus + panitumumab in refractory solid tumors [117]
Phase I trial of cetuximab and erlotinib in solid tumors [119]
Phase I trial of dasatinib + cetuximab in advanced solid tumors [120]